Dextech Medical AB

Equities

DEX

SE0005881489

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.1 ^SEK	+4.51%		-5.56%	+29.77%

Apr. 26	Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Apr. 15	DexTech Medical Announces New Positive Results from the Myeloma Study	CI

DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex

February 18, 2022 at 03:04 am EST

DexTech Medical will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer.

Latest news about Dextech Medical AB

Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	Apr. 26	CI
DexTech Medical Announces New Positive Results from the Myeloma Study	Apr. 15	CI
Dextech Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 15	CI
Dextech Medical AB Announces Positive Results from the Myeloma Study	Jan. 23	CI
DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated	Dec. 13	CI
Dextech Medical AB Reports Earnings Results for the First Quarter Ended September 30, 2023	23-10-27	CI
Dextech Medical AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-08-30	CI
Dextech Medical AB Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-04-28	CI
Dextech Medical AB Informs About the Myeloma Study	23-03-27	CI
Dextech Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-15	CI
Dextech Medical AB Reports Earnings Results for the First Quarter Ended September 30, 2022	22-10-27	CI
Dextech Medical AB Announces Upcoming Multiple Myeloma Study	22-09-27	CI
Dextech Medical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2022	22-08-30	CI
DexTech Medical Gets Swedish Nod for Early-Stage Multiple Myeloma Drug Study	22-08-10	MT
Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency	22-08-10	CI
Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member	22-05-11	CI
Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-04-29	CI
DexTech's Board Proposes Chairman Candidate	22-04-06	MT
DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex	22-02-18	CI
Dextech Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-15	CI
Dextech Medical AB Reports Earnings Results for the First Quarter Ended September 30, 2021	21-10-22	CI
Dextech Medical AB Appoints Håkan Åström to its Board	21-10-07	CI
Dextech Medical AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2021	21-08-30	CI
Dextech Medical AB Reports Earnings Results of the Fourth Quarter and Year Ended June 30, 2021	21-08-30	CI

Chart Dextech Medical AB

Duration

Period

More charts

Company Profile

Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DEXTECH MEDICAL AB	+29.77%	8.59M
VERTEX PHARMACEUTICALS INCORPORATED	-1.65%	104B
REGENERON PHARMACEUTICALS, INC.	+6.75%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.60%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-10.17%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	14.39B
SAREPTA THERAPEUTICS, INC.	+35.47%	12.37B

Bio Therapeutic Drugs